What is therapeutic duplication?
Understanding duplicate medications, their impact on claimant safety and costs, and how to identify and prevent them in insurance claims.
Published: 3 April 2026 | Updated: 3 April 2026
The Definition and Problem of Therapeutic Duplication
Therapeutic duplication occurs when a claimant is simultaneously taking two or more medications from the same drug class or with the same pharmacological effect. In essence, the medications are redundant; they're providing overlapping treatment for the same clinical condition. The claimant is paying for (and your scheme is funding) medication effects that are duplicated, rather than benefiting from additive or complementary therapy.
Classic examples include taking two different blood pressure medications from the same class, two different pain medications simultaneously, or two medications for depression or anxiety. While the medications may have slightly different side effect profiles or specific indications, the core therapeutic action is duplicated. This duplication creates safety risks, increases cost, and complicates medication management without improving outcomes.
How Therapeutic Duplication Develops in Claims
Scenario 1: Multiple Prescribers, Limited Coordination
Your claimant sees a GP who prescribes pain medication for injury-related pain, then sees a physiotherapist who recommends over-the-counter pain relief, then visits an orthopaedic surgeon who prescribes a different pain medication. Without medication review, the claimant ends up on three pain medications simultaneously. None of the prescribers aware of the others' recommendations. This is particularly common in workers compensation and CTP claims involving multiple providers.
Scenario 2: Medication Switching Without Cessation
A prescriber changes a claimant from one depression medication to another (perhaps due to side effects or inadequate effectiveness) but forgets to explicitly stop the first medication. The claimant continues taking both. If the claimant fills prescriptions from a pharmacy that uses a generic dispensing model, the duplication might go unnoticed.
Scenario 3: Addition Without Deprioritisation
A claimant on a pain medication that provides partial benefit is prescribed a second pain medication with different characteristics, hoping to improve analgesia. However, the first medication continues at full dose. The result is duplication with unintended polypharmacy escalation.
Scenario 4: Confusion Between Brand and Generic Names
A claimant prescribed ibuprofen (a generic pain reliever) later visits another doctor and receives a prescription for Nurofen (the brand name for ibuprofen). If the claimant doesn't realise these are the same drug, they may take both, creating duplication. This is particularly problematic when one is prescribed and the other is purchased over-the-counter.
Types of Therapeutic Duplication
Same Class Duplication
The claimant is on two medications from the same drug class. For example, two beta-blockers (heart/blood pressure medications), two selective serotonin reuptake inhibitors (depression medications), or two nonsteroidal anti-inflammatory drugs. The medications have different brand names and perhaps slight pharmacokinetic differences, but they serve the same therapeutic purpose.
| Condition | Drug Class | Example Duplication | Outcome |
|---|---|---|---|
| Pain | NSAID | Ibuprofen + Naproxen | Increased GI bleeding risk; no improved analgesia |
| High blood pressure | ACE inhibitor | Lisinopril + Enalapril | Excessive blood pressure lowering; hyperkalemia risk |
| Depression | SSRI | Sertraline + Citalopram | Increased serotonin; serotonin syndrome risk |
| Sleep | Benzodiazepine | Diazepam + Temazepam | Excessive sedation; overdose risk |
Pharmacological Duplication
Two medications achieve the same therapeutic effect but are from different classes. For example, a claimant on a prescription pain reliever and also using topical pain relief, or on a psychiatric medication plus herbal supplements for mood. The effect overlaps even though the medications are structurally different.
Ingredient Duplication
A combination medication (containing multiple ingredients) is taken alongside a single-ingredient medication containing one of those same ingredients. For example, a claimant taking a cold and flu combination product (containing paracetamol, decongestant, and antihistamine) while also taking a separate paracetamol tablet. This increases paracetamol to potentially dangerous levels.
The Clinical and Financial Consequences
Safety Risks
Therapeutic duplication increases medication-related adverse events. Higher doses of the same drug effect increase risks of side effects, overdose, and organ damage. Drug interactions become more likely. For example, two NSAIDs simultaneously increase gastrointestinal bleeding risk; two sedating medications increase fall risk in older patients. Your liability exposure increases when you're funding duplicative therapy.
Reduced Efficacy
Paradoxically, duplication may reduce clinical benefit. A claimant expecting improved pain relief from two pain medications might experience increased side effects without improved analgesia. They lose confidence in medications and may become non-adherent or frustrated with the treatment plan.
Cost Escalation
Your scheme is funding redundant medication benefits. If one pain medication is sufficient for the claimant's needs, funding a second duplicates cost without clinical benefit. Over months or years, this accumulates to substantial unnecessary expenditure.
Medication Complexity and Confusion
Claimants on duplicative therapies take more tablets, have more complex regimens, and are at higher risk of non-adherence. They may not understand why they're on multiple seemingly similar medications, reducing their engagement in their own treatment.
Identifying Therapeutic Duplication in Your Claims
Red Flags for Therapeutic Duplication
- Claimant on multiple medications for the same symptom (multiple pain medications, multiple sleep aids)
- Multiple prescribers without documented coordination
- Medication list includes brand name and generic equivalent (Nurofen and ibuprofen)
- Combination medications plus separate single-ingredient medications (cold and flu tablet plus separate paracetamol)
- Medications from the same drug class with different prescribed dates
- Claimant confusion about why they're on multiple medications
- Over-the-counter medications taken alongside prescription medications for the same condition
- Claimant reports side effects inconsistent with a single medication (suggests overmedication)
Systematic Screening Approach
A comprehensive medication review systematically screens for duplication by categorising medications by therapeutic class and purpose. This simple step reveals any redundancy. For complex claims with multiple prescribers, systematic screening is essential. It's particularly important to ask claimants about over-the-counter medications, herbal products, and supplements, which are often not recorded on prescription lists but can create duplication.
Strategies to Prevent and Resolve Duplication
Prevention Through Coordination
Encourage claimants to use a single pharmacy (ensuring the pharmacist has complete medication visibility) and provide all prescribers with a complete medication list. Case management that includes regular medication review reduces duplication risk. For high-risk claims (multiple prescribers, complex conditions), proactive medication screening at 4-8 week intervals is cost-effective.
Resolving Existing Duplication
Once identified, recommend consolidation to a single agent from each therapeutic class. This requires prescriber consultation to ensure appropriate medication selection (choosing the medication with best side effect profile for the individual claimant) and coordinated cessation of the duplicate. A medication review typically proposes which duplicate should continue and which should cease, with clinical rationale.
Supporting the Transition
When stopping a duplicate medication, ensure the claimant understands the change and isn't confused by receiving fewer prescriptions. Some medications require gradual tapering (benzodiazepines, certain antidepressants) to avoid withdrawal symptoms. Clear communication prevents the claimant re-requesting the old medication or misunderstanding the change as deprioritisation of their care.
Key Takeaways for Insurers
- Therapeutic duplication means the claimant is taking two or more medications with overlapping effects
- Develops commonly in fragmented care systems with multiple prescribers and limited coordination
- Increases safety risks, cost, and medication complexity without improving outcomes
- Can involve same-class drugs, pharmacologically similar medications, or ingredient overlap
- Systematic medication review identifies duplication quickly and inexpensively
- Resolution involves choosing the most appropriate single agent and ceasing the duplicate
- Particularly important to screen for duplication in claims with multiple prescribers
- Prevents duplication through centralised pharmacy use and regular medication review
Is Your Claimant on Duplicate Medications?
Therapeutic duplication is common in multi-provider claims and often unintentional. A medication review identifies redundant medications, proposes consolidation to single agents, and eliminates unnecessary costs while improving safety. For claims with multiple prescribers or complex medication regimens, screening for duplication is a quick, high-value intervention.
Request a Medication Review
